StreetInsider.com News Articles

Oppenheimer Starts Ocugen, Inc. (OCGN) at Outperform

Wed, 11 Mar 2026 06:03:09 -0400

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen, Inc. (NASDAQ: OCGN) with a Outperform rating and a price target of $10.00.

The analyst comments "We view Ocugen as an emerging gene therapy leader in blinding ocular disorders. Lead asset OCU400 is in Phase 3 for retinitis pigmentosa (RP, ~100K in US), for which a potential 2027 approval could provide near-term entry into a sizable and poorly-met rare disease market opportunity. Programs for two other progressively degenerative retinal diseases, Stargardt (~30K in US) and geographic atrophy (GA, >1M in US), are not far behind—mgmt. anticipates three FDA applications over the next three

Oppenheimer Starts Ocugen, Inc. (OCGN) at Outperform

Wed, 11 Mar 2026 06:03:09 -0400

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen, Inc. (NASDAQ: OCGN) with a Outperform rating and a price target of $10.00.

Form 3 Ocugen, Inc. For: Mar 04 Filed by: Johnson-Greene Treerita Essalima

Thu, 05 Mar 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260305/26116407.html

Form 3 Ocugen, Inc. For: Mar 04 Filed by: Johnson-Greene Treerita Essalima

Thu, 05 Mar 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260305/26116407.html

Form S-8 Ocugen, Inc.

Wed, 04 Mar 2026 12:23:00 -0400

si-local-file:///var/storage/secattach/20260304/26109452.html

Form S-8 Ocugen, Inc.

Wed, 04 Mar 2026 12:23:00 -0400

si-local-file:///var/storage/secattach/20260304/26109452.html

Form 10-K Ocugen, Inc. For: Dec 31

Wed, 04 Mar 2026 11:38:00 -0400

si-local-file:///var/storage/secattach/20260304/26109178.html

Form 10-K Ocugen, Inc. For: Dec 31

Wed, 04 Mar 2026 11:38:00 -0400

si-local-file:///var/storage/secattach/20260304/26109178.html

Form 8-K Ocugen, Inc. For: Mar 04

Wed, 04 Mar 2026 11:12:00 -0400

si-local-file:///var/storage/secattach/20260304/26109020.html

Form 8-K Ocugen, Inc. For: Mar 04

Wed, 04 Mar 2026 11:12:00 -0400

si-local-file:///var/storage/secattach/20260304/26109020.html

Form 8-K Ocugen, Inc. For: Mar 04

Wed, 04 Mar 2026 11:08:00 -0400

si-local-file:///var/storage/secattach/20260304/26109001.html

Form 8-K Ocugen, Inc. For: Mar 04

Wed, 04 Mar 2026 11:08:00 -0400

si-local-file:///var/storage/secattach/20260304/26109001.html

Ocugen (OCGN) Reports In-Line Q4 EPS

Wed, 04 Mar 2026 08:19:50 -0400

Ocugen (NASDAQ: OCGN) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Ocugen (OCGN) click here.

Ocugen completes Phase 3 enrollment for retinitis pigmentosa gene therapy

Wed, 04 Mar 2026 08:15:38 -0400

Ocugen Inc. (NASDAQ: OCGN) completed enrollment for its OCU400 Phase 3 clinical trial targeting retinitis pigmentosa, the company reported in its fourth quarter 2025 financial results. The liMeliGhT trial enrolled 140 patients and topline data is expected in the first quarter of 2027.

The biotechnology company reported a net loss of $0.06 per share for the fourth quarter of 2025, compared to a $0.05 loss in the same period of 2024. For the full year 2025, the net loss per share was $0.23 versus $0.20 in 2024.

Research and development expenses increased to $39.8 million for 2025 from $32.1 million in 2024.

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 08:15:00 -0400

Conference Call and Webcast Today at 8:30 a.m. ET

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.
OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.
OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026.

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 08:15:00 -0400

Conference Call and Webcast Today at 8:30 a.m. ET
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.
OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.
OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026.

Ocugen completes enrollment for phase 3 retinitis pigmentosa trial

Mon, 02 Mar 2026 07:02:15 -0400

Ocugen Inc. (NASDAQ: OCGN) announced completion of enrollment for its Phase 3 liMeliGhT clinical trial testing OCU400, a gene therapy for retinitis pigmentosa. The trial enrolled 140 patients randomized 2:1 between treatment and control groups across multiple genetic mutations.

The company expects topline data from the one-year trial in the first quarter of 2027. Ocugen plans to use these results to support its Biologics License Application filing and potential approval in 2027. The European Medicines Agency has indicated acceptability of the U.S.-based trial for a Marketing Authorization Application.

The trial targets patients with early- to late-stage retinitis pigmentosa, including pediatric patients aged

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mon, 02 Mar 2026 07:02:00 -0400

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients
Topline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP
Positive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically meaningful, approximately 2-line LLVA gain, reinforcing durable gene-agnostic benefit

MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mon, 02 Mar 2026 07:02:00 -0400

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients
Topline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RP
Positive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically meaningful, approximately 2-line LLVA gain, reinforcing durable gene-agnostic benefit

MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Wed, 18 Feb 2026 07:02:00 -0400

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646)

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Wed, 18 Feb 2026 07:02:00 -0400

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646)

Form 8-K Ocugen, Inc. For: Feb 09

Mon, 09 Feb 2026 07:59:00 -0400
si-local-file:///var/storage/secattach/20260209/25964983.html

Form 8-K Ocugen, Inc. For: Feb 09

Mon, 09 Feb 2026 07:59:00 -0400
si-local-file:///var/storage/secattach/20260209/25964983.html

Ocugen names Rita Johnson-Greene as chief financial officer

Mon, 09 Feb 2026 07:02:15 -0400

Ocugen Inc. (NASDAQ: OCGN) appointed Rita Johnson-Greene as chief financial officer, the biotechnology company announced February 9.

Johnson-Greene brings more than 20 years of healthcare experience to the role. She most recently served as chief operating officer at the Alliance for Regenerative Medicine, where she led operations, finance, and global expansion initiatives. Prior to that position, she was vice president of sales and qualified treatment centers at Genetix Biotherapeutics, where she built pre-commercial sales and operations teams to support gene therapy product launches.

Johnson-Greene also held senior leadership positions at Spark Therapeutics and supported the launch of LUXTERNA. She previously worked in

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Mon, 09 Feb 2026 07:02:00 -0400

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO).

“Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of